- Home
- BVFL vs TLSI Comparison
BVFL vs TLSI Comparison
Compare BVFL & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- TLSI
- Stock Information
- Founded
- BVFL 1873
- TLSI 2010
- Country
- BVFL United States
- TLSI United States
- Employees
- BVFL N/A
- TLSI N/A
- Industry
- BVFL Savings Institutions
- TLSI Medical Specialities
- Sector
- BVFL Finance
- TLSI Health Care
- Exchange
- BVFL Nasdaq
- TLSI Nasdaq
- Market Cap
- BVFL 160.7M
- TLSI 160.4M
- IPO Year
- BVFL N/A
- TLSI N/A
- Fundamental
- Price
- BVFL $15.26
- TLSI $5.52
- Analyst Decision
- BVFL
- TLSI Strong Buy
- Analyst Count
- BVFL 0
- TLSI 6
- Target Price
- BVFL N/A
- TLSI $11.75
- AVG Volume (30 Days)
- BVFL 13.7K
- TLSI 67.6K
- Earning Date
- BVFL 04-21-2025
- TLSI 03-27-2025
- Dividend Yield
- BVFL N/A
- TLSI N/A
- EPS Growth
- BVFL N/A
- TLSI N/A
- EPS
- BVFL 1.10
- TLSI N/A
- Revenue
- BVFL $37,904,000.00
- TLSI $29,431,000.00
- Revenue This Year
- BVFL N/A
- TLSI $55.43
- Revenue Next Year
- BVFL N/A
- TLSI $50.09
- P/E Ratio
- BVFL $13.87
- TLSI N/A
- Revenue Growth
- BVFL N/A
- TLSI 58.99
- 52 Week Low
- BVFL $10.16
- TLSI $3.50
- 52 Week High
- BVFL $18.19
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- BVFL 47.07
- TLSI 52.49
- Support Level
- BVFL $15.26
- TLSI $5.23
- Resistance Level
- BVFL $15.97
- TLSI $5.72
- Average True Range (ATR)
- BVFL 0.40
- TLSI 0.35
- MACD
- BVFL 0.03
- TLSI 0.02
- Stochastic Oscillator
- BVFL 45.38
- TLSI 78.72
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. It offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, business checking as well as certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.